Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dostarlimab in Stage II and III dMMR Colon Cancers
NCT05239546Phase 2Recruiting
- Sponsor
- University of Iowa
- Start
- Mar 2023
- Primary completion
- Jun 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab in colon cancer, sponsored by University of Iowa. Primary endpoint: Major Clinical Response Rate at 18 weeks. Started Mar 2023; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05239546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239546.